RT Journal Article
T1 Turning the spotlight to cholinergic pharmacotherapy of the human language system
A1 Dávila-Arias, María Guadalupe
A1 Torres-Prioris, María José
A1 López-Barroso, Diana
A1 Berthier-Torres, Marcelo Luis
K1 Farmacología experimental
K1 Neurofarmacología
K1 Neurolingüística
K1 Mecanismos colinérgicos
AB Even though language is essential in human communication, research on pharmacological therapies for language deficits in highly prevalent neurodegenerative and vascular brain diseases has received little attention. Emerging scientific evidence suggests that disruption of the cholinergic system may play an essential role in language deficits associated with Alzheimer's disease and vascular cognitive impairment, including post-stroke aphasia. Therefore, current models of cognitive processing are beginning to appraise the implications of the brain modulator acetylcholine in human language functions. Future work should be directed further to analyze the interplay between the cholinergic system and language, focusing on identifying brain regions receiving cholinergic innervation susceptible to modulation with pharmacotherapy to improve affected language domains. The evaluation of language deficits in pharmacological cholinergic trials for Alzheimer's disease and vascular cognitive impairment has thus far been limited to coarse-grained methods. More precise, fine-grained language testing is needed to refine patient selection for pharmacotherapy to detect subtle deficits in the initial phases of cognitive decline. Additionally, noninvasive biomarkers can help identify cholinergic depletion. However, despite the investigation of cholinergic treatment for language deficits in Alzheimer's disease and vascular cognitive impairment, data on its effectiveness are insufficient and controversial. In the case of post-stroke aphasia, cholinergic agents are showing promise, particularly when combined with speech-language therapy to promote trained-dependent neural plasticity. Future research should explore the potential benefits of cholinergic pharmacotherapy in language deficits and investigate optimal strategies for combining these agents with other therapeutic approaches.
PB Springer Nature
YR 2023
FD 2023-05-24
LK https://hdl.handle.net/10630/27070
UL https://hdl.handle.net/10630/27070
LA eng
NO Dávila, G., Torres-Prioris, M.J., López-Barroso, D. et al. Turning the Spotlight to Cholinergic Pharmacotherapy of the Human Language System. CNS Drugs (2023). https://doi.org/10.1007/s40263-023-01017-4
NO Funding for open access publishing: Universidad Málaga/CBUA. Guadalupe Dávila was supported by the Junta de Andalucía,Spain (Grant: P20_00501). Marcelo L. Berthier has been supportedby the European Social Fund (FEDER: EQC2018-004803-P). María José Torres-Prioris was supported by a Margarita Salas postdoctoral fellowship by the University of Malaga, funded by the European Union, NextGenerationEU, and the Spanish Ministerio de Universidades.Diana López-Barroso was supported by the Ayuda RYC2020-029495-I Ramón y Cajal funded by the MCIN/AEI/10.13039/501100011033 and by El FSE invierte en tu futuro; and by the Grant PID2021-127617NAI00 Proyecto de Generación de Conocimiento 2021 funded by MCIN/AEI/10.13039/501100011033 and FEDER Una manera de hacerEuropa. Funding for the open access charge: Universidad de Málaga/CBUA
DS RIUMA. Repositorio Institucional de la Universidad de Málaga
RD 20 ene 2026